Latest news with #SatishMehta
The Print
4 hours ago
- Business
- The Print
Jaipur Foot maker BMVSS invited to UN to showcase work on disability welfare
The statement said that the organisation holds a special consultative status with the Economic and Social Council of the United Nations. 'Seven years ago the United Nations organized a special meeting of permanent representatives of various member countries to showcase the Jaipur Foot,' it said. According to the statement, BMVSS Founder and Chief Patron D R Mehta and Chairman Satish Mehta will make presentations in two sessions on Tuesday, which will be attended by permanent representatives of various countries and other dignitaries. Jaipur, Jun 8 (PTI) Shri Bhagwan Mahavir Viklang Sahayata Samiti (BMVSS), known globally for its 'Jaipur Foot' and rehabilitation for persons with disabilities has been invited to the United Nations headquarters in New York to present its initiatives for disability welfare, a statement issued here said. The organisation has held 114 special camps in various countries in recent years in collaboration with the Ministry of External Affairs (MEA) and rehabilitated more than 50,000 disabled persons from 44 countries. The United Nations has specially invited BMVSS to discuss various issues related to the disabled (Divyangs) as it has worked extensively in India and abroad, the statement added. Last year, former President of the United Nations General Assembly Dennis Francis had specially visited the BMVSS centre to know the manufacturing process of Jaipur Foot. PTI AG OZ OZ This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
News18
6 hours ago
- Health
- News18
Jaipur Foot maker BMVSS invited to UN to showcase work on disability welfare
Jaipur, Jun 8 (PTI) Shri Bhagwan Mahavir Viklang Sahayata Samiti (BMVSS), known globally for its 'Jaipur Foot' and rehabilitation for persons with disabilities has been invited to the United Nations headquarters in New York to present its initiatives for disability welfare, a statement issued here said. According to the statement, BMVSS Founder and Chief Patron D R Mehta and Chairman Satish Mehta will make presentations in two sessions on Tuesday, which will be attended by permanent representatives of various countries and other dignitaries. The statement said that the organisation holds a special consultative status with the Economic and Social Council of the United Nations. 'Seven years ago the United Nations organized a special meeting of permanent representatives of various member countries to showcase the Jaipur Foot," it said. The organisation has held 114 special camps in various countries in recent years in collaboration with the Ministry of External Affairs (MEA) and rehabilitated more than 50,000 disabled persons from 44 countries. The United Nations has specially invited BMVSS to discuss various issues related to the disabled (Divyangs) as it has worked extensively in India and abroad, the statement added. Last year, former President of the United Nations General Assembly Dennis Francis had specially visited the BMVSS centre to know the manufacturing process of Jaipur Foot. PTI AG OZ OZ
Hindustan Times
10 hours ago
- General
- Hindustan Times
NGO working for welfare of PwD invited to UN to present its work
Jaipur, NGO Bhagwan Mahaveer Viklang Sahayata Samiti , renowned for its work for the welfare of persons with disabilities , has been invited to the United Nations headquarters in New York to present its work for the welfare of people with disabilities. BMVSS Founder and Chief Patron D R Mehta and President Satish Mehta will present the work on Tuesday in two sessions, which will be attended by permanent representatives of various countries and other dignitaries. "BMVSS has special consultative status with the Economic and Social Council of the UNO and seven years ago the United Nations organised a special meeting of the Permanent Representatives of various members nations to showcase Jaipur Foot, which in recent years has held 114 special camps in various countries in association with the Ministry of External Affairs and rehabilitated over 50,000 disabled persons of 44 countries," a release from the organisation said. "The United Nations which are holding the seminar to discuss the various issues related to the disabled has specially invited BMVSS because of the massive work undertaken by it both in India and abroad and rehabilitated 2.4 million persons with disabilities," the release said. The BMVSS offers artificial limbs and other aids and appliances free of charge to differently-abled people, and it is known for its Jaipur Foot . "D R Mehta would stress on the various means to rehabilitate the disabled as according to the World Health Organization 15 percent of the world's population is affected by various disabilities and there is an urgent need for finding a solution for their rehabilitation," the release added. According to the release, India's Permanent Representatives in the United Nations P Harish is holding another meeting in New York on Wednesday in which the permanent representatives of various nations would be apprised about the initiative taken by the Ministry of External Affairs under the "India For Humanities" for rehabilitating the differently-abled people of Asia, Africa and Latin America. The India For Humanities programme is jointly run by the MEA and the BMVSS, in which special camps are organised in various countries to rehabilitate the disabled.
Mint
23-05-2025
- Business
- Mint
Shark Tank's Namita Thappar-backed Emcure Pharma shares surge 20% in two sessions after robust Q4 earnings
Shares of Emcure Pharmaceuticals were locked in the 10 per cent upper circuit at ₹ 1,288.65 on Friday, May 23, as the stock extended its rally to the second straight session. The rally comes on the back of a strong performance for the quarter ended March 2025 (Q4FY25). The stock had already surged nearly 9 per cent in the previous session, taking its total two-day gain to about 20 per cent. As of the March 2025 quarter, Shark Tank judge Namita Vikas Thapar owns 50.71 lakh shares or a 2.68 per cent stake of the firm. Emcure reported a 64 per cent year-on-year (YoY) jump in consolidated net profit to ₹ 189 crore in Q4FY25, compared to ₹ 115 crore in the same quarter last year. The revenue from operations rose 20 per cent YoY to ₹ 2,116 crore, up from ₹ 1,771 crore. Sequentially, the company's net profit grew 26.4 per cent, while revenue increased by 7.8 per cent from the previous quarter's net profit of ₹ 156 crore and revenue of ₹ 1,936 crore. According to Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, 'The company delivered a very strong performance in Q4, with all business segments contributing to growth. On the domestic side, we expanded our covered market and built a strong product pipeline. In international markets, we are seeing approvals for our differentiated offerings.' NSE filing by Emcure highlighted strong traction in both domestic and international operations: Domestic business revenue surged 24.8 per cent YoY to ₹ 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. International business also expanded, growing 15.6 per cent YoY to ₹ 1,187 crore, led by a 39.3 per cent YoY jump in revenue from the Rest of the World segment to ₹ 481 crore. 1,187 crore, led by a 39.3 per cent YoY jump in revenue from the Rest of the World segment to 481 crore. In Canada, revenue rose 6.2 per cent YoY to ₹ 310 crore, with Mantra—its recent acquisition—now fully integrated. In the European Union, revenue posted a modest 1.7 per cent rise, supported by a recently acquired product portfolio and new regulatory approvals. The company stated that it remains focused on improving margins through new product launches and operating efficiencies, which will be key priorities in FY26. The Board of Directors also recommended a final dividend of ₹ 3 per equity share of face value ₹ 10 each (30 per cent of face value) for the financial year ended March 31, 2025. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM) and will be paid within the regulatory timelines once approved. Emcure's stock has gained nearly 28 per cent from its IPO price of ₹ 1,008, with the company debuting on the bourses in July 2024. Currently, the pharma stock trades 18 per cent below its record high of ₹ 1,577.50, touched in September 2024. However, it has recovered sharply, rising 45 per cent from its 52-week low of ₹ 890, hit in April 2025. In May 2025 alone, the scrip has jumped over 25 per cent, rebounding from a 5 per cent dip in April. Before that, it gained 9 per cent in March, but had declined 20 percent in February and 15 per cent in January, indicating a recent shift in sentiment.
Mint
23-05-2025
- Business
- Mint
Emcure Pharmaceuticals shares surge 20% in two sessions after robust Q4 earnings
Shares of Emcure Pharmaceuticals were locked in a 10 percent upper circuit at ₹ 1,288.65 on Friday, May 23, as the stock extended its rally for a second straight session. The rally comes on the back of a strong performance for the quarter ended March 2025 (Q4FY25). The stock had already surged nearly 9 percent in the previous session, taking its total two-day gain to about 20 percent. As of the March 2025 quarter, Shark Tank judge Namita Vikas Thapar owns 50.71 lakh share or a 2.68 percent stake of the firm. Emcure reported a 64 percent year-on-year (YoY) jump in consolidated net profit to ₹ 189 crore in Q4FY25, compared to ₹ 115 crore in the same quarter last year. The revenue from operations rose 20 percent YoY to ₹ 2,116 crore, up from ₹ 1,771 crore. Sequentially, the company's net profit grew 26.4 percent, while revenue increased by 7.8 percent from the previous quarter's net profit of ₹ 156 crore and revenue of ₹ 1,936 crore. According to Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, 'The company delivered a very strong performance in Q4, with all business segments contributing to growth. On the domestic side, we expanded our covered market and built a strong product pipeline. In international markets, we are seeing approvals for our differentiated offerings.' NSE filing by Emcure highlighted strong traction in both domestic and international operations: Domestic business revenue surged 24.8 percent YoY to ₹ 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. International business also expanded, growing 15.6 percent YoY to ₹ 1,187 crore, led by a 39.3 percent YoY jump in revenue from the Rest of the World segment to ₹ 481 crore. In Canada, revenue rose 6.2 percent YoY to ₹ 310 crore, with Mantra—its recent acquisition—now fully integrated. In the European Union, revenue posted a modest 1.7 percent rise, supported by a recently acquired product portfolio and new regulatory approvals. The company stated that it remains focused on improving margins through new product launches and operating efficiencies, which will be key priorities in FY26. The Board of Directors also recommended a final dividend of ₹ 3 per equity share of face value ₹ 10 each (30 percent of face value) for the financial year ended March 31, 2025. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM), and will be paid within the regulatory timelines once approved. Emcure's stock has gained nearly 28 percent from its IPO price of ₹ 1,008, with the company debuting on the bourses in July 2024. Currently, the pharma stock trades 18 percent below its record high of ₹ 1,577.50, touched in September 2024. However, it has recovered sharply, rising 45 percent from its 52-week low of ₹ 890, hit in April 2025. In May 2025 alone, the scrip has jumped over 25 percent, rebounding from a 5 percent dip in April. Before that, it gained 9 percent in March, but had declined 20 percent in February and 15 percent in January, indicating a recent shift in sentiment. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
